logo-loader
RNS
Haleon PLC

Haleon PLC - Transactions in Own Shares

RNS Number : 6036E
Haleon PLC
18 May 2026
 

Icon Description automatically generated

 

Haleon plc: Aggregated information - transactions in own shares

 

18 May 2026: Haleon plc (the "Company" or "Haleon") today announces the purchase of 8,316,688 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 12 March 2026.

 


London Stock Exchange

CBOE (UK)/BXE

CBOE (UK)/CXE

Aquis

Date of purchase:

11 May 2026

Number of Shares purchased:

1,338,672

850,639

989,996

-

Highest price paid per Share (p):

333.1000

333.0000

333.0000

-

Lowest price paid per Share (p):

326.6000

326.6000

326.6000

-

Volume weighted average price paid per Share (p):

328.7510

328.3012

328.5150

-

Date of purchase:

12 May 2026

Number of Shares purchased:

136,968

73,601

88,439

-

Highest price paid per Share (p):

332.0000

330.9000

332.0000

-

Lowest price paid per Share (p):

325.4000

325.4000

325.4000

-

Volume weighted average price paid per Share (p):

327.7318

327.9542

327.6454

-

Date of purchase:

13 May 2026

Number of Shares purchased:

607,723

502,225

490,052

-

Highest price paid per Share (p):

331.7000

331.7000

331.7000

-

Lowest price paid per Share (p):

329.9000

329.9000

329.9000

-

Volume weighted average price paid per Share (p):

330.9437

330.8733

330.9219

-

Date of purchase:

14 May 2026

Number of Shares purchased:

487,742

353,903

407,856

-

Highest price paid per Share (p):

332.8000

332.8000

332.8000

-

Lowest price paid per Share (p):

329.4000

329.4000

329.4000

-

Volume weighted average price paid per Share (p):

331.1191

331.1758

331.1625

-

Date of purchase:

15 May 2026

Number of Shares purchased:

950,986

408,698

629,188

-

Highest price paid per Share (p):

332.3000

332.3000

332.3000

-

Lowest price paid per Share (p):

329.0000

329.0000

329.0000

-

Volume weighted average price paid per Share (p):

330.7060

330.7844

330.7188

-

 

Following the settlement of the above, the Company's registered share capital is 8,871,945,578 ordinary shares of £0.01 each, of which 12,130,560 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,859,815,018 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/6036E_1-2026-5-15.pdf

 

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

 

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

 

Enquiries

 

 

Investors

Media

 

Jo Russell  

+44 7787 392441

Zoë Bird

+44 7736 746167

Rakesh Patel     

+44 7552 484646

Victoria Durman

+44 7894 505730

Email: investor-relations@haleon.com

Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

 

For more information, please visit www.haleon.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSBLGDURSBDGLU
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read